CommercialCoverageMedium impact
08.02.02a, Ublituximab-xiiy (Briumvi®) for intravenous use
Independence Blue Cross·Oncology, Hematology, Neurology +1 more·Pharmacy
Effective date
Jul 9, 2025
We identified it
Jun 19, 2026
Summary
Insurance policy for Ublituximab-xiiy (Briumvi®), an intravenous medication, has been updated with a reissue effective July 9, 2025. This appears to be a commercial insurance policy update for this specialized infusion drug used in certain medical conditions.
Action Required
By July 9, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage, prior authorization requirements, or billing procedures for Ublituximab-xiiy (Briumvi®) infusions. Update billing protocols and staff training as needed based on the complete policy content.